Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2020

February 2020 | 558 pages | ID: CA2C4AF7B2FEN
Global Markets Direct

Abstracts

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure - Pipeline Review, H1 2020, provides an overview of the Congestive Heart Failure (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. There are two types of heart failure including systolic heart failure (left ventricle loses its ability to contract normally) and diastolic heart failure (left ventricle loses its ability to relax normally). The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 11, 31, 23, 2, 76 and 24 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 20 and 4 molecules, respectively.

Congestive Heart Failure (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Congestive Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Congestive Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Congestive Heart Failure (Heart Failure) - Overview
Congestive Heart Failure (Heart Failure) - Therapeutics Development
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development
Congestive Heart Failure (Heart Failure) - Drug Profiles
Congestive Heart Failure (Heart Failure) - Dormant Projects
Congestive Heart Failure (Heart Failure) - Discontinued Products
Congestive Heart Failure (Heart Failure) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Congestive Heart Failure (Heart Failure) - Pipeline by 4TEEN4 Pharmaceuticals GmbH, H1 2020
Congestive Heart Failure (Heart Failure) - Pipeline by Actelion Pharmaceuticals Ltd, H1 2020
Congestive Heart Failure (Heart Failure) - Pipeline by Adrenomed AG, H1 2020
Congestive Heart Failure (Heart Failure) - Pipeline by AgeX Therapeutics Inc, H1 2020
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2020
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2020
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2020 (Contd..1), H1 2020
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2020 (Contd..2), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4TEEN4 Pharmaceuticals GmbH
Actelion Pharmaceuticals Ltd
Adrenomed AG
AgeX Therapeutics Inc
Amgen Inc
Anchored Rsk3 Inhibitors LLC
Araim Pharmaceuticals Inc
ARCA biopharma Inc
Arena Pharmaceuticals Inc
Armaron Bio Pty Ltd
Armgo Pharma Inc
Ascelegen Therapeutics Inc
Ascendia Pharmaceuticals LLC
Astellas Pharma Inc
AstraZeneca Plc
Athersys Inc
Bayer AG
BEAT BioTherapeutics Corp
Betagenon AB
BioCardia Inc
BioStem Technologies Inc
BlueRock Therapeutics
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
C&C BioPharma LLC
Capricor Therapeutics Inc
Cardiac RSK3 Inhibitors LLC
Cardiol Therapeutics Inc
Cardior Pharmaceuticals GmbH
Cardiora Pty Ltd
CCRP Therapeutics GmbH
Celixir Ltd
CuronBiotech Inc
Cyclerion Therapeutics Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
Elevian Inc
Ethicare GmbH
Exscien Corp
F. Hoffmann-La Roche Ltd
G3 Pharmaceuticals Inc
GBSciences Inc
Gmax Biopharm Ltd
Heartseed Inc
Hemostemix Inc
Hyloris Pharmaceuticals SA
I-Cordis LLC
iHeart Japan Corp
Immunwork Inc
Innolife Co Ltd
Innopharmax Inc
Inserm Transfert SA
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
IsletOne AB